PRTN3 and rheumatoid arthritis: We identified 8 patients with RA who were negative for anti‐CCP2 but positive for either or both of the fine specificities (Figure 1A), increasing the overall diagnostic sensitivity with ACPA from 84.5% obtained with anti‐CCP2 alone to 87% if all 3 assays were combined.